Leaders across pharma, biotech, CROs, and clinical research come together at CNS Summit to advance drug development through collaboration and innovation.

IMA Clinical Research conducts studies across a wide range of CNS indications, including Alzheimer’s disease, ADHD, anxiety, major depressive disorder, psychedelics, and PTSD. Our teams bring experienced investigators and raters who drive consistent site performance and high-quality data across CNS trials. Attending CNS Summit: Priya Selvarajah, MD, MBA, Regional Site Director; Eli Shalenberg, MD, Principal Investigator; and Kevin Short, Director of Business Development.

We look forward to continuing the conversation at CNS Summit.